Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

被引:32
作者
Ripa, Rasmus S. [1 ,2 ]
Zobel, Emilie H. [3 ]
von Scholten, Bernt J. [3 ,4 ]
Jensen, Jacob K. [1 ,2 ]
Binderup, Tina [1 ,2 ]
Diaz, Lars J. [3 ]
Curovic, Viktor R. [3 ]
Hansen, Tine W. [3 ]
Rossing, Peter [2 ,3 ]
Kjaer, Andreas [1 ,2 ]
机构
[1] Rigshosp, Dept Clin Physiol Nucl Med & PET & Cluster Mol Im, Dept Biomed Sci, Copenhagen, Denmark
[2] Univ Copenhagen, Copenhagen, Denmark
[3] Steno Diabet Ctr Copenhagen, Niels Steensens Vej 2, Gentofte, Denmark
[4] Novo Nordisk AS, Soborg, Denmark
关键词
atherosclerosis; cardiovascular diseases; carotid arteries; glucagon-like peptide 1; inflammation; Type; 2; Diabetes; EUROPEAN ASSOCIATION; RECEPTOR AGONIST; VASCULAR-DISEASE; CAROTID-ARTERY; F-18-FDG PET; PLAQUE; RISK; APOE(-/-);
D O I
10.1161/CIRCIMAGING.120.012174
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The mechanism behind the cardiovascular protection observed with human GLP-1 RA (glucagon-like peptide-1 receptor agonists) in type 2 diabetes is unknown. We hypothesized that treatment with the GLP-1 RA liraglutide had a positive effect on vascular inflammation. Methods: LIRAFLAME (Effect of liraglutide on vascular inflammation in type-2 diabetes: A randomized, placebocontrolled, double-blind, parallel clinical PET/CT trial) was a double-blind, randomized controlled trial performed at a single university hospital clinic in Denmark. Patients with type 2 diabetes were via computer-generated randomization list assigned (1:1) liraglutide up to 1.8 mg or placebo once daily for 26 weeks. The primary end point was change in vascular inflammation over 26 weeks assessed by [F-18]-fluorodeoxyglucose positron emission tomography/computed tomography. Analyses were based on intention-to-treat. Key secondary outcomes included change in other indices of atherosclerosis. Results: Between October 26, 2017, and August 16, 2019, 147 patients were screened and 102 were randomly assigned to liraglutide (n=51) or placebo (n=51) and 99 (97%) completed the trial. Change in the [F-18]-fluorodeoxyglucose positron emission tomography measure of vascular inflammation (active-segment target-to-background ratio) did not differ between treatment groups: change from baseline to 26 weeks was -0.04 (95% CI, -0.17 to 0.08) in the liraglutide group compared with -0.09 (-0.19 to 0.01) in the placebo group (mean difference, 0.05 [95% CI, -0.11 to 0.21], P=0.53). Secondary analyses restricted to [F-18]-fluorodeoxyglucose positron emission tomography of the carotid arteries as well as other indices of atherosclerosis confirmed the primary result. We performed an explorative analysis of interaction between treatment group and history of cardiovascular disease (P=0.052). Conclusions: In this low to moderate risk population with type 2 diabetes, liraglutide did not change vascular inflammation assessed as [F-18]-fluorodeoxyglucose uptake compared with placebo. An explorative analysis indicated a possible effect in persons with history of cardiovascular disease, in line with current guidelines where liraglutide is recommended to patients with history of cardiovascular disease. Registration: URL: ; Unique identifier: NCT03449654.
引用
收藏
页数:13
相关论文
共 33 条
  • [1] QUANTIFICATION OF CORONARY-ARTERY CALCIUM USING ULTRAFAST COMPUTED-TOMOGRAPHY
    AGATSTON, AS
    JANOWITZ, WR
    HILDNER, FJ
    ZUSMER, NR
    VIAMONTE, M
    DETRANO, R
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 15 (04) : 827 - 832
  • [2] 18Fluorodeoxyglucose Accumulation in Arterial Tissues Determined by PET Signal Analysis
    Al-Mashhadi, Rozh H.
    Tolbod, Lars P.
    Bloch, Lars O.
    Bjorklund, Martin M.
    Nasr, Zahra P.
    Al-Mashhadi, Zheer
    Winterdahl, Michael
    Frokiaer, Jorgen
    Falk, Erling
    Bentzon, Jacob F.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (09) : 1220 - 1232
  • [3] Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
    Arakawa, Masayuki
    Mita, Tomoya
    Azuma, Kosuke
    Ebato, Chie
    Goto, Hiromasa
    Nomiyama, Takashi
    Fujitani, Yoshio
    Hirose, Takahisa
    Kawamori, Ryuzo
    Watada, Hirotaka
    [J]. DIABETES, 2010, 59 (04) : 1030 - 1037
  • [4] Sirtuin 6 Expression and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Incretin Treatment
    Balestrieri, Maria Luisa
    Rizzo, Maria Rosaria
    Barbieri, Michelangela
    Paolisso, Pasquale
    D'Onofrio, Nunzia
    Giovane, Alfonso
    Siniscalchi, Mario
    Minicucci, Fabio
    Sardu, Celestino
    D'Andrea, Davide
    Mauro, Ciro
    Ferraraccio, Franca
    Servillo, Luigi
    Chirico, Fabio
    Caiazzo, Pasquale
    Paolisso, Giuseppe
    Marfella, Raffaele
    [J]. DIABETES, 2015, 64 (04) : 1395 - 1406
  • [5] Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis
    Bucerius, Jan
    Hyafil, Fabien
    Verberne, Hein J.
    Slart, Riemer H. J. A.
    Lindner, Oliver
    Sciagra, Roberto
    Agostini, Denis
    Uebleis, Christopher
    Gimelli, Alessia
    Hacker, Marcus
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (04) : 780 - 792
  • [6] 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    Buse, John B.
    Wexler, Deborah J.
    Tsapas, Apostolos
    Rossing, Peter
    Mingrone, Geltrude
    Mathieu, Chantal
    D'Alessio, David A.
    Davies, Melanie J.
    [J]. DIABETES CARE, 2020, 43 (02) : 487 - 493
  • [7] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
    Dormandy, JA
    Charbonnel, B
    Eckland, DJA
    Erdmann, E
    Massi-Benedetti, M
    Kmoules, IK
    Skene, AM
    Tan, MH
    Lefébvre, PJ
    Murray, GD
    Standl, E
    Wilcox, RG
    Wlhelmsen, L
    Betteridge, J
    Birkeland, K
    Golay, A
    Heine, RJ
    Korányi, L
    Laakso, M
    Mokán, M
    Norkus, A
    Pirags, V
    Podar, T
    Scheen, A
    Scherbaum, W
    Schernthaner, G
    Schmitz, O
    Skrha, J
    Smith, U
    Taton, J
    [J]. LANCET, 2005, 366 (9493) : 1279 - 1289
  • [8] Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
    Everett, Brendan M.
    Donath, Marc Y.
    Pradhan, Aruna D.
    Thuren, Tom
    Pais, Prem
    Nicolau, Jose C.
    Glynn, Robert J.
    Libby, Peter
    Ridker, Paul M.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (21) : 2392 - 2401
  • [9] Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
    Fayad, Zahi A.
    Mani, Venkatesh
    Woodward, Mark
    Kallend, David
    Abt, Markus
    Burgess, Tracy
    Fuster, Valentin
    Ballantyne, Christie M.
    Stein, Evan A.
    Tardif, Jean-Claude
    Rudd, James H. F.
    Farkouh, Michael E.
    Tawakol, Ahmed
    [J]. LANCET, 2011, 378 (9802) : 1547 - 1559
  • [10] The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-/- mouse model
    Gaspari, Tracey
    Welungoda, Iresha
    Widdop, Robert E.
    Simpson, Richard W.
    Dear, Anthony E.
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2013, 10 (04) : 353 - 360